XFOR
X4 Pharmaceuticals Inc
NASDAQ: XFOR · HEALTHCARE · BIOTECHNOLOGY
$4.07
-0.73% today
Updated 2026-04-30
Market cap
$374.59M
P/E ratio
—
P/S ratio
10.67x
EPS (TTM)
$-1.87
Dividend yield
—
52W range
$1 – $5
Volume
0.5M
X4 Pharmaceuticals Inc (XFOR) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-225.60%
Operating margin
-931.00%
ROE
-76.00%
ROA
-22.90%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2015 | — | $-13.22M | — | — | — |
| 2016 | $0.00 | $-22.98M | — | — | — |
| 2017 | $0.00 | $-33.88M | — | — | — |
| 2018 | $3.50M | $-33.28M | -2.94% | -831.00% | -951.00% |
| 2019 | $3.00M | $-52.81M | -22.40% | -1,560.10% | -1,760.23% |
| 2020 | $3.00M | $-62.13M | 100.00% | -1,995.80% | -2,071.03% |
| 2021 | $0.00 | $-88.70M | — | — | — |
| 2022 | $0.00 | $-93.87M | — | — | — |
| 2023 | $0.00 | $-101.17M | — | — | — |
| 2024 | $2.56M | $-37.45M | 68.83% | -1,423.58% | -1,464.61% |
| 2025 | $35.11M | $-79.20M | 82.18% | -247.44% | -225.55% |